Install
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
- 913articles · 365d
- 2+ hour agolatest article
- Sep 14, 2025earliest in window
- 95%with images
- 285avg words
- Medical 573
- Business & Industrial 538
- Economy, Business & Finance 451
- Health & Wellness 337
- Health 267
- Finance & Business 254
- Science & Technology 156
- Science & Nature 42
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge
3+ mon, 1+ week ago (353+ words) FDA's CBER details a framework for sponsors to apply existing CMC, nonclinical, and clinical data to genome-editing-based product development and regulatory filings. When finalized, the guidance is intended to reduce redundant testing, lower development costs, and accelerate patient access to…...
Pharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burden
3+ mon, 1+ week ago (13+ words) New FDA Draft Guidance Targets Gene Therapy Submission Burden | PharmExec PharmExec.com...
The Situation We Faced: The Development and Commercialization of MariTide
11+ mon, 3+ day ago (301+ words) Chris Spivey, Director of Industrial Relations and Strategic Partnerships for Industry Sciences One at MJH Life Sciences, and Raymond J. Deshaies, PhD, Executive Officer of Molecular Biology at the California Institute of Technology, discuss the development of MariTide, which is in…...
Chiesi Group & Arbor Biotechnologies Announce Global Strategic Partnership Aiming to Develop Gene Editing Program ABO-101
11+ mon, 5+ day ago (206+ words) Chiesi Group partners with Arbor Biotechnologies to advance gene editing therapies for rare diseases, focusing on primary hyperoxaluria type 1. The collaboration and license agreement includes the development and global commercialization of ABO-101 for primary hyperoxaluria type 1 and the development of…...